| How many drug targets are there? JP Overington, B Al-Lazikani, AL Hopkins Nature reviews Drug discovery 5 (12), 993-996, 2006 | 4638 | 2006 |
| ChEMBL: a large-scale bioactivity database for drug discovery A Gaulton, LJ Bellis, AP Bento, J Chambers, M Davies, A Hersey, Y Light, ... Nucleic acids research 40 (D1), D1100-D1107, 2012 | 4329 | 2012 |
| A comprehensive map of molecular drug targets R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ... Nature reviews Drug discovery 16 (1), 19-34, 2017 | 2289 | 2017 |
| The genome of the blood fluke Schistosoma mansoni M Berriman, BJ Haas, PT LoVerde, RA Wilson, GP Dillon, GC Cerqueira, ... Nature 460 (7253), 352-358, 2009 | 1221 | 2009 |
| Standard conformations for the canonical structures of immunoglobulins B Al-Lazikani, AM Lesk, C Chothia Journal of molecular biology 273 (4), 927-948, 1997 | 1178 | 1997 |
| Combinatorial drug therapy for cancer in the post-genomic era B Al-Lazikani, U Banerji, P Workman Nature biotechnology 30 (7), 679-692, 2012 | 1135 | 2012 |
| Therapeutic opportunities within the DNA damage response LH Pearl, AC Schierz, SE Ward, B Al-Lazikani, FMG Pearl Nature Reviews Cancer 15 (3), 166-180, 2015 | 561 | 2015 |
| Defective acute inflammation in Crohn's disease: a clinical investigation DJB Marks, MWN Harbord, R MacAllister, FZ Rahman, J Young, ... The Lancet 367 (9511), 668-678, 2006 | 527 | 2006 |
| Genomic-scale prioritization of drug targets: the TDR Targets database F Agüero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ... Nature reviews Drug discovery 7 (11), 900-907, 2008 | 367 | 2008 |
| Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance D Gonzalez de Castro, PA Clarke, B Al‐Lazikani, P Workman Clinical Pharmacology & Therapeutics 93 (3), 252-259, 2013 | 313 | 2013 |
| Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets DC Wedge, G Gundem, T Mitchell, DJ Woodcock, I Martincorena, M Ghori, ... Nature genetics 50 (5), 682-692, 2018 | 244 | 2018 |
| Protein structure prediction B Al-Lazikani, J Jung, Z Xiang, B Honig Current opinion in chemical biology 5 (1), 51-56, 2001 | 206 | 2001 |
| Drug discovery in advanced prostate cancer: translating biology into therapy TA Yap, AD Smith, R Ferraldeschi, B Al-Lazikani, P Workman, ... Nature reviews Drug discovery 15 (10), 699-718, 2016 | 157 | 2016 |
| Objective assessment of cancer genes for drug discovery MN Patel, MD Halling-Brown, JE Tym, P Workman, B Al-Lazikani Nature reviews Drug discovery 12 (1), 35-50, 2013 | 156 | 2013 |
| Large-scale profiling of kinase dependencies in cancer cell lines J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ... Cell reports 14 (10), 2490-2501, 2016 | 125 | 2016 |
| Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation C Abad-Zapatero, O Perišić, J Wass, AP Bento, J Overington, ... Drug discovery today 15 (19-20), 804-811, 2010 | 125 | 2010 |
| canSAR: an updated cancer research and drug discovery knowledgebase JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ... Nucleic acids research 44 (D1), D938-D943, 2016 | 108 | 2016 |
| The kinase polypharmacology landscape of clinical PARP inhibitors AA Antolin, M Ameratunga, U Banerji, PA Clarke, P Workman, ... Scientific reports 10 (1), 2585, 2020 | 107 | 2020 |
| Minimum information about a bioactive entity (MIABE) S Orchard, B Al-Lazikani, S Bryant, D Clark, E Calder, I Dix, O Engkvist, ... Nature reviews Drug discovery 10 (9), 661-669, 2011 | 106 | 2011 |
| The Lancet Commission on prostate cancer: planning for the surge in cases ND James, I Tannock, J N'Dow, F Feng, S Gillessen, SA Ali, B Trujillo, ... The Lancet 403 (10437), 1683-1722, 2024 | 105 | 2024 |
Paul WorkmanChief Executive & President, Institute of Cancer Research, LondonVerified email at icr.ac.uk
